A Phase 1 Study of AZD1775 in Combination With Belinostat in Relapsed and Refractory Myeloid Malignancies and Selected Untreated Patients With Acute Myeloid Leukemia

Trial Profile

A Phase 1 Study of AZD1775 in Combination With Belinostat in Relapsed and Refractory Myeloid Malignancies and Selected Untreated Patients With Acute Myeloid Leukemia

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs AZD-1775 (Primary) ; Belinostat (Primary)
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 26 Jan 2017 Planned number of patients changed from 13 to 30.
    • 26 Jan 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top